OVERVIEW: The Stanley Medical Research Institute (SMRI) now only funds treatment trials for drugs aimed at treating bipolar disorder and schizophrenia.
IP TAKE: SMRI is interested primarily in drug trials that can show results quickly, i.e. within five years.
PROFILE: The Stanley Medical Research Institute awards grants for the research of drugs aimed at treating bipolar disorder and schizophrenia. Related grants are awarded out of its Treatment Trials and Drug Development Program, which is aimed at testing the efficacy of drugs that pharmaceutical companies want nothing to do with, including drugs that have lost patent protection, repurposed drugs and off-label indications.
The majority of SMRI’s grants go toward the research and development of new treatments, including the repurposing of current drugs used for other illnesses to treat bipolar and schizophrenia. The maximum grant amount is $300,000 for up to three years. Stanley only supports research which can be completed and provide results within five years.
Applying for the grants themselves is easy enough. There is an online application and a helpful FAQ section to make filling out the questionnaire as painless as possible. One recommendation from the website: keep your request economical — i.e., only ask for the amount you really need, not the amount you really want.
Application deadlines are typically around the first of October. The number of grants given out each year varies depending on the number of grantees already pocketing money, but the number of trials being funded tends to fall between 50 and 60 at any given time.
- Maree Webster, Executive Director
- E. Fuller Torrey, Associate Director of Research
- John Davis, Associate Director of Treatment Trials
- Mark Weiser, Associate Director of Treatment Trials